Wire Stories
EpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License Agreement
SHANGHAI & BARCELONA, Spain–(BUSINESS WIRE)–EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies, and Almirall, a global...